OverviewSuggest Edit
Eutilex ((주)유틸렉스) is a biotech company developing anti-tumor T-cell therapy. Additionally, it offers antibody therapeutics based on its proprietary immunotherapy technology.
| Type | Public | |
| Founded | 2015 | |
| HQ | KR | Map |
| Website | eutilex.com |
Locations
Key People/Management at Eutilex
Byoung S. Kwon
CEO
Soo Young Choi
COO
Hoon-Sung Jeh
CTO
Edwin E. Kwon
CFO
Jeonghoon Han
CBO
Young Ho Kim
CDO
Eutilex Financials and Metrics
Eutilex Revenue
Market capitalization (15-Jan-2021) | 379.8b |
Closing stock price (15-Jan-2021) | 52.1k |
Eutilex's current market capitalization is ₩379.8 b.
Eutilex Cybersecurity Score
Eutilex Online and Social Media Presence
Eutilex's Trends
Eutilex Frequently Asked Questions
When was Eutilex founded?
Eutilex was founded in 2015.
Who are Eutilex key executives?
Eutilex's key executives are Byoung S. Kwon, Soo Young Choi and Hoon-Sung Jeh.
Who are Eutilex competitors?
Competitors of Eutilex include Alpha Tau Medical, Foghorn Therapeutics and Gossamer Bio.
Where are Eutilex offices?
Eutilex has an office in.
How many offices does Eutilex have?
Eutilex has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies